Drug Trial Radar · NCT00674921
Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda
Last checked: Nov 20, 2026Latest source record: Jun 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,650
Planned (sponsor's estimate)
Start
Jun 2008
Primary completion
Jun 2011
Study completion Jun 2011
Sponsor
- Lead sponsor
- MRC/UVRI and LSHTM Uganda Research UnitAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council
- First posted
- May 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 16 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
According to the national guidelines in Uganda and to the World Health Organization guidelines, HIV-infected patients should receive cotrimoxazole prophylaxis indefinitely. There are, however, concerns regarding the indefinite application of cotrimoxazole prophylaxis among patients immunologically stabilized on HAART (e.g. high pill burden, drug-drug interactions, toxicity and poor adherence because of treatment fatigue). To date no empirical evidence is available regarding the safety and optimal timing for the cessation of cotrimoxazole prophylaxis among HAART patients who successfully restored immunological competence. Research question: Does morbidity significantly differ between continuation (orthodox) and cessation (experimental) of cotrimoxazole prophylaxis among immuno-competent patients stable HAART in the resource-limited setting of Uganda?
Conditions
- HIV Infections
Interventions
cotrimoxazoleDrug
cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
PlaceboDrug
starch, magnesium stearate, sodium lauryl sulphate
Primary outcomes
What the sponsor says the trial is designed to measure.
- all-cause morbidity such as pneumonia or malaria (presumptive and definitive diagnosis)Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MRC/UVRI Uganda Research Unit on Aids
Entebbe, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.